None
Conditions
Interventions
Phase One dixon sequential group:Using the Dixon sequential method to determine the ED50 and ED95 of esmolol in inhibiting hemodynamic responses related to intubation during the induction of anesthesi
Phase Two:Experimental Group O:Group O was administered esketamine (ED95 dose, given as a weight-based intravenous push in µg/kg)
Phase Two: control group S:Group S was given sufentanil at an equivalent analgesic dose calculated from Group O (administered as a weight-based µg/kg IV bolus)
Sponsors
Handan First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–65 years; 2. Patients planned for elective surgery under general anesthesia requiring endotracheal intubation; 3. ASA class I–II and stable class III; 4. Body mass index (BMI) 18.0–30.0 kg/m^2; 5. No use of sedatives, opioids, or strong CYP2D6 inhibitors within 24 hours before surgery.
Exclusion criteria
Exclusion criteria: 1. Antiscipation of difficult airway; 2. Severe cardiovascular disease, respiratory disease, neurological disease, moderate to severe liver and kidney insufficiency; 3. Allergy to ocelidine, sufentanil or related drugs; 4. Pregnant or lactating women; 5. History of regular use of opioids or psychotropic drugs within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change of mean arterial pressure?MAP%;Rate Pressure Product ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Airway reactions: incidence of reactions during anesthetic induction intubation and coughing;Safety indicators: Record the occurrence of adverse events such as hypertension, hypotension, tachycardia, and bradycardia.; | — |
Countries
China
Contacts
Public ContactQingqing Shen/Huayong Song
Handan First Hospital
Outcome results
None listed